SCHEMBL18591898

SCHEMBL18591898

CCCOc1ccc(OCC(=O)O)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.45
▸ L3MBTL1 Q9Y468 2/20 0.45
▸ TSHR P16473 2/20 0.45
▸ LMNA P02545 2/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ ACACB O00763 2/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ MAPT P10636 3/20 0.44
▸ PLA2G4B P0C869 1/20 0.44
▸ NR4A1 P22736 1/20 0.42
▸ APEX1 P27695 1/20 0.42
▸ MCL1 Q07820 1/20 0.42
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ PPARG P37231 1/20 0.41
▸ BLM P54132 1/20 0.41
▸ PPARD Q03181 1/20 0.41
▸ PPARA Q07869 1/20 0.41
▸ PTPN7 P35236 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16796518 0.82 LMNA (0.51) ALDH1A1LMNASMN1; SMN2ALOX15MAPT
SCHEMBL5275333 0.81 L3MBTL1 (0.64) ALDH1A1L3MBTL1TSHRLMNASMN1; SMN2
SCHEMBL10716298 0.79 ACACB (0.51) L3MBTL1TSHRLMNASMN1; SMN2ACACB
SCHEMBL18530410 0.76 CA12 (0.51) SMN1; SMN2
SCHEMBL13534998 0.76 ALDH1A1 (0.46) ALDH1A1L3MBTL1TSHRLMNASMN1; SMN2
SCHEMBL16421193 0.76 ALDH1A1 (0.49) ALDH1A1L3MBTL1TSHRLMNASMN1; SMN2
SCHEMBL10657063 0.76 MAPT (0.75) L3MBTL1TSHRMAPT
SCHEMBL29416383 0.75 ALOX15 (0.52) ALDH1A1TSHRLMNASMN1; SMN2ALOX15
SCHEMBL2435587 0.75 ALOX15 (0.52) ALDH1A1TSHRLMNASMN1; SMN2ALOX15
SCHEMBL5429541 0.74 PLA2G4B (0.68) ALDH1A1TSHRLMNAALOX15PLA2G4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230263893-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS ARVINAS OPERATIONS, INC. 2023-08-24 — — US disclosed
US-20170065719-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS ARVINAS OPERATIONS, INC. 2017-03-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230263893-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS BRPF3, STUB1, BRDT ALDH1A1 3365/4885L3MBTL1 1673/4885TSHR 3658/4885
US-20170065719-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS BRPF3, STUB1, BRDT ALDH1A1 3365/4885L3MBTL1 1673/4885TSHR 3658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback